Atrioventricular block after COVID-19: What is the mechanism, site of block, and treatment?

Heart Rhythm

Cardiology Division, Department of Medicine, University of California San Francisco, San Francisco, California. Electronic address:

Published: March 2021

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hrthm.2020.10.020DOI Listing

Publication Analysis

Top Keywords

atrioventricular block
4
block covid-19
4
covid-19 mechanism
4
mechanism site
4
site block
4
block treatment?
4
atrioventricular
1
covid-19
1
mechanism
1
site
1

Similar Publications

Background: To investigate the toxicity of N-n-butyl haloperidol iodide (F2), a quaternary ammonium salt derivative of haloperidol, in mice for potential therapeutic purposes.

Methods: The acute median lethal dose (LD) of F2 was determined using the Bliss method following intravenous administration in mice. Routine surface electrocardiograms (ECGs) and arterial blood pressures (aBPs) were recorded under general anesthesia in untreated and pharmacologically vagotomized mice injected with F2.

View Article and Find Full Text PDF

A 3-year-old spayed male mixed-breed Labrador presented to the Emergency and Critical Care Unit with lethargy, loss of appetite, vomiting, a recent history of presyncopal episodes, and severe exercise intolerance. On admission, the patient had bradycardia, low blood pressure, and mild abdominal pain. Serum biochemistry information revealed severe hyperkalemia, hyponatremia, hypoglycemia, and mildly increased liver and kidney parameters.

View Article and Find Full Text PDF

Background: High-intensity endurance training induces specific cardiac adaptations, often observed through electrocardiographic (ECG) changes. This study investigated the prevalence of ECG abnormalities in national-level Australian triathletes compared to sedentary controls.

Methods: A cross-sectional observational study was conducted involving 22 triathletes and 7 sedentary controls.

View Article and Find Full Text PDF

Background: Cardiac sarcoidosis (CS) is a chronic inflammatory disease characterised by non-caseating granulomas, while arrhythmogenic cardiomyopathy (ACM) is a genetic condition mainly affecting desmosomal proteins. The coexistence of CS and genetic variants associated with ACM is not well understood, creating challenges in diagnosis and management. This study aimed to describe the clinical, imaging and genetic features of patients with both conditions.

View Article and Find Full Text PDF

The increasing use of immune checkpoint inhibitors in clinical practice is associated with a broad spectrum of immune-related adverse events, such as cardiac, rheumatological and neurological toxicities. Myocarditis is a life-threatening complication, and the concurrent development of myocarditis, myositis and/or myasthenia leads to difficulties in diagnosis, management and treatment. We describe a case presenting with this triple M overlap syndrome following pembrolizumab treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!